In your experience with the rulemaking process, do the industry participants in the administrative process of rulemaking to some degree control the pace of that rulemaking through ...
But if you are a chemical company and you have a chemical that you see, uh-oh, there are some problems coming out here, ...
It's really important that we solve the question of ownership of this data.
There's a role for government in protecting against some of the abuses that are possible here.
This is a bipartisan issue. It's about doing it right versus doing it wrong, doing it stupid versus doing it smart, and ...
What I see over and over again is bills that come to the floor or bills that come to the committee that should be bipart...
This has always been a strongly bipartisan bill. There has been a lot of support for it.
This bill has a new section that wasn't in, I don't think I have ever seen it before in the earlier versions of the Spor...
It's time for a reboot of the Meaningful Use Program. It's been run for quite a while now.
That data should be ultimately the property of the patient, not of anybody else.
This is not big government forcing anybody's hand. This is not a mandate.